- recruitingPHASE3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
This study is for children aged 6 months to 17 years with long-term kidney disease (CKD) and too much protein in their urine. It tests a new medicine called finerenone to see if it can improve kidney health alongside existing treatments. Researchers want to check how safe and effective it is.
United States · Argentina · Australia - active not recruitingPHASE2
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
This study looks at a new medicine, vicadrostat, combined with empagliflozin, for adults with chronic kidney disease. Participants will take pills daily for 3 months, with regular checks on their kidney health and general well-being. It aims to see if starting medicines at different times impacts results.
United States · Argentina · Australia - active not recruitingPHASE3
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
This study looks at a new medicine called ravulizumab for people with kidney disease having heart surgery. It aims to see if the medicine can prevent serious kidney problems after the operation. It's for adults aged 18-90.
United States · Argentina · Australia - active not recruitingPHASE3
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
This study investigates if a new drug, ziltivekimab, can lower the risk of heart attacks and strokes in people with heart disease, kidney disease, and ongoing inflammation. Participants will receive either the drug or a dummy treatment to see if it makes a difference.
United States · Argentina · Australia - active not recruiting
What Are the Determinations of Adult Progressive CKD? The Renal Impairment In Secondary Care (RIISC) Study
This study, called RIISC, wants to understand why some people with chronic kidney disease (CKD) get worse over time. By looking closely at people at higher risk, researchers hope to find better ways to predict and treat CKD, improving care for everyone.
United Kingdom - recruitingPHASE3
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
This study for children aged 2-17 with kidney disease looks at a medicine called empagliflozin. We want to see if it helps their kidneys and how well their body handles it. Participants take the medicine or a dummy pill for 6 months, then everyone takes the medicine for a year.
United States · Argentina · Australia - authorisedHuman Pharmacology (Phase I)- Other
A study to learn about how a new nurandociguat tablet is absorbed and processed in the body compared to an old tablet and how food affects the way the new tablet is absorbed and processed in the body
This study is looking at a new tablet, called nurandociguat, for people with long-term kidney problems. We want to understand how the body takes in and uses this new tablet, especially when compared to an older version and how food might change this process.
Germany - authorisedTherapeutic exploratory (Phase II)
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)
This study is looking at a new treatment called Survodutide for people with Chronic Kidney Disease (CKD). It aims to see if this treatment can help reduce a protein called albumin in the urine, which is a sign of kidney damage.
Germany · Spain · Netherlands - ongoing, recruitingTherapeutic exploratory (Phase II)
(22040 ALPINE 1) A Phase 2b dose-finding, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of BAY 3283142 on top of standard of care in reducing albuminuria in patients with chronic kidney disease
This study is testing a new medicine, BAY 3283142, for people with long-term kidney disease. We want to see if it helps reduce kidney damage by lowering a protein called albumin in your urine, compared to a dummy pill. It's a key step to finding better treatments.
Belgium · Sweden · Spain - ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
This study is testing a new medicine, Orforglipron, for adults with type 2 diabetes and who are overweight or obese. It's looking at how well it works compared to an insulin called Glargine to protect against heart problems.
Greece · Germany · Austria - ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4 mg/2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people with chronic kidney disease and type 2 diabetes living with overweight or obesity.
This study looks at a new combination medicine, CagriSema, for people with type 2 diabetes, kidney disease, and overweight or obesity. It compares CagriSema to existing treatments and a dummy medicine to see how it affects kidney health, weight, and blood sugar, while checking for side effects.
Spain · Hungary · Poland - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.
This study is looking at a new medicine called BAY3283142. We want to understand how it travels through the body when healthy people take it with another medicine called atazanavir. The main goal is to see how much of BAY3283142 gets into the blood after someone swallows it.
Netherlands - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study in healthy men to learn about how the body absorbs, processes, and removes radioactively labeled BAY 3283142
This study is looking at how a new drug, BAY 3283142, moves through the bodies of healthy men. It will help scientists understand how the body uses and gets rid of this medicine to treat chronic kidney disease.
Netherlands - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to learn about the safety of BAY 3283142 in people with mild to moderate high blood pressure
This study is looking at a new medicine called BAY 3283142. It’s for adults who have slightly high blood pressure and ongoing kidney problems. We want to see how safe the medicine is and if it causes any side effects at different doses.
Germany - authorisedPhase I and Phase II (Integrated)- Other
A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD)
This study looks at how a medicine called dapagliflozin affects the heart in people with long-term kidney disease. Researchers want to see if it changes the heart's size and how well it pumps after six months. Half the people will get the medicine, and half will get a dummy pill.
Denmark - recruiting
Optical Coherence Tomography And NEphropathy: The OCTANE Study
This study looks at changes in eye blood vessels in people with high blood pressure and kidney disease, compared to healthy individuals. It uses a simple eye scan (OCT) to see if these changes happen and if treatments help improve them.
United Kingdom - authorisedTherapeutic exploratory (Phase II)
SGLT2 INHIBITION (DAPAGLIFLOZIN) IN DIABETIC AND NON-DIABETIC HEMODIALYSIS PATIENTS WITH AND WITHOUT RESIDUAL URINE VOLUME: A PROSPECTIVE RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PHASE II TRIAL
This study looks at a medicine called dapagliflozin (Forxiga) for people on dialysis with kidney problems, both with and without diabetes. We want to see if it helps reduce a common heart issue called Left Ventricular Hypertrophy, which is when the heart muscle thickens.
Austria - recruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Argentina · Australia · Austria - recruitingPHASE3
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
This study looks at a new medicine called roxadustat for children and teenagers with kidney disease and low red blood cells (anemia). It's a pill, hoping to be a new way to treat this condition instead of injections.
Belgium · Bulgaria · Croatia - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants with Established Atherosclerotic Cardiovascular and Chronic Kidney Disease
This study is testing a new medicine, AZD4144, for people who have both long-term kidney problems and heart disease caused by hardened arteries. We're looking at its safety, how well people tolerate it, and what it does in the body. It's a very early stage of research.
Bulgaria · Romania · Hungary - authorisedHuman Pharmacology (Phase I)- Other
A study to learn how safe nurandociguat is when taken with sildenafil in men with arterial hypertension.
This study is looking at how safe a new medicine called nurandociguat is when taken with sildenafil (Viagra) by men who have high blood pressure. It's an early stage study to understand how these two medicines work together in the body.
Germany - authorisedHuman Pharmacology (Phase I)- Other
(22597) A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coronary artery disease.
This study is looking at how a new drug, nurandociguat, works with a common heart medicine, nitroglycerin, in people with heart artery disease. The main goal is to check if this combination is safe and how it affects the body.
Germany · Bulgaria - authorisedTherapeutic exploratory (Phase II)
Efficacy and safety of SP16 in preventing Acute Kidney Injury in at-risk subjects with chronic kidney disease undergoing elective cardiac surgery using the heart-lung-machine: A prospective, randomized, double-blind, placebo-controlled clinical trial (EASE-AKI)
This study looks at a new treatment, SP16, to see if it can protect kidneys in people with existing kidney problems who are having heart surgery. It aims to prevent a complication called Acute Kidney Injury (AKI) that can happen after surgery.
Germany - authorisedHuman Pharmacology (Phase I)- First administration to humans
A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease
This study is testing a new medicine, OJR520, for people with kidney disease and healthy volunteers. The main goals are to check if it's safe, how the body handles it, and if it has any effects. It’s a carefully designed study where some people get the medicine and others get a dummy treatment.
Germany · Romania - authorisedTherapeutic use (Phase IV)
CANIDIAP; CANagliflozin In DIAlysis Patients
This study is looking at how a kidney medicine called canagliflozin (known as Invokana) works in people on dialysis. We want to see how much of the medicine reaches certain parts of the body, which helps us understand if it's working as intended.
Netherlands - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to learn more about how safe nurandociguat is and how it affects the way the body processes rosuvastatin and dabigatran in healthy adults
This study is looking at a new medicine called nurandociguat in healthy adults. It wants to find out if it's safe and how it interacts with two other common medicines, rosuvastatin (for cholesterol) and dabigatran (a blood thinner), to understand its effects better.
Germany - recruiting
Improving chronic kidney disease identification and assessing its association with health inequalities in coding practices
This study aims to improve how a long-term kidney condition (CKD) is found and recorded in GP notes. It uses a new computer tool to make sure nearly everyone with CKD gets the right care and no one is wrongly coded.
United Kingdom · England - recruitingPHASE3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
This study looks at how safe a new medicine called finerenone is for children and young people (aged 1-18) with long-term kidney disease, when taken with other common kidney medicines. It also checks if it helps reduce protein in their urine.
United States · Argentina · Australia